RxDoctor Payments DataLook up a doctor →

Vincent Nguyen, MD

Family Medicine · Baton Rouge, LANPI 1053459644

Payments from drug & device makers

$13,475in general payments, 2019–2025

Across 561 payments — averaging $24.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Novo Nordisk$2K
  • GSK$1K
  • Amgen$1K
  • Pfizer$794
  • Amarin Pharma, Inc.$726
  • plus $5K from 36 others

What the payments were for

  • Food & beverage$13,465100%
  • Education$100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,475 in reported general payments places this provider in the 95th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$19,365
Medicare patients
51
Services billed
5,063

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide46$70,530
MounjaroTirzepatide33$64,975
FarxigaDapagliflozin Propanediol57$53,023
Tresiba Flextouch U-200Insulin Degludec43$41,249
JardianceEmpagliflozin35$37,695
TrulicityDulaglutide19$21,442
LinzessLinaclotide17$16,204
Synjardy XrEmpagliflozin/Metformin Hcl13$11,593
VascepaIcosapent Ethyl22$11,328
KerendiaFinerenone16$10,559
Omega-3 Acid Ethyl Esters63$6,471
DiovanValsartan12$4,962
SynthroidLevothyroxine Sodium40$4,190
Liothyronine Sodium66$3,195
Atorvastatin Calcium326$2,648

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$439$86,41752 claims
Novo NordiskOzempic$1,766$70,53046 claims
AstraZenecaFarxiga$631$53,02357 claims
Boehringer IngelheimJardiance, Synjardy Xr$262$49,28848 claims
AbbVieLinzess, Synthroid$3,225$20,39457 claims
BayerKerendia$152$10,55916 claims
NovartisDiovan$36$4,96212 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$42$1,445139 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →